Lightnews — Scholar-powered news

The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 12h

New Review

Core outcome measurement set for clinical trials in dengue: an international Delphi consensus study (DEN-CORE)

www.thelancet.com/journals/lan...

Core outcome measurement set for clinical trials in dengue: an international Delphi consensus study (DEN-CORE)

Dengue, caused by any one of four distinct virus serotypes, is the most rapidly spreading mosquito-borne viral disease worldwide. It is a primary arboviral infection with increasing global incidence, ...

www.thelancet.com

2 1

The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 12h

New Review

The Emerging Resistance Index: tracking early resistance to new antibiotics

www.thelancet.com/journals/lan...

The Emerging Resistance Index: tracking early resistance to new antibiotics

The high clinical burden of antimicrobial resistance (AMR) and the dwindling antibiotic pipeline demand standardised tools to monitor resistance development to new antibiotics. The Emerging Resistance...

www.thelancet.com

2

The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 12h

New Comment

Xpert-Ultra for diagnosing asymptomatic tuberculosis

www.thelancet.com/journals/lan...

Xpert-Ultra for diagnosing asymptomatic tuberculosis

Xpert MTB/RIF Ultra outperforms its predecessor, the Xpert MTB/RIF assay, in tuberculosis diagnosis, particularly in cases of paucibacillary disease (infection with very low bacterial load).1,2 This i...

www.thelancet.com

The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 12h

New Research

Long-term risk of tuberculosis among individuals with Xpert Ultra trace screening results in Uganda: a longitudinal follow-up study

www.thelancet.com/journals/lan...

Long-term risk of tuberculosis among individuals with Xpert Ultra trace screening results in Uganda: a longitudinal follow-up study

Individuals with trace-positive sputum during screening have a substantial 2-year risk of tuberculosis, even when extensive initial evaluations do not confirm disease. Treatment should be considered f...

www.thelancet.com

1 2 1

The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 12h

New comment

Household transmission of mpox in Africa: limited in adults but more prevalent in children

www.thelancet.com/journals/lan...

Household transmission of mpox in Africa: limited in adults but more prevalent in children

In the transmission of infectious diseases, epidemiological and social context is key, and mpox is a perfect example. Before 2022, transmission was largely believed to be zoonotic, with only limited h...

www.thelancet.com

1

The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 12h

New Research

Characterising household transmission dynamics of clade Ib mpox in Burundi: a prospective cohort study

www.thelancet.com/journals/lan...

Characterising household transmission dynamics of clade Ib mpox in Burundi: a prospective cohort study

Intrahousehold transmission of clade 1b mpox in Burundi was limited, and unlikely to sustain a broader community spread. The involvement of children in transmission chains within the household undersc...

www.thelancet.com

1 1 1

The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 12h

New Research

Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial

www.thelancet.com/journals/lan...

Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised t...

Among patients with a hospital-acquired or health-care-associated Gram-negative bloodstream infection, cefiderocol resulted in non-inferior 14-day mortality compared with standard of care. Adverse eve...

www.thelancet.com

2 1

The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 7d

New comment:

Improving antimalarial therapeutic efficacy studies

www.thelancet.com/journals/lan...

Improving antimalarial therapeutic efficacy studies

Malaria, mostly due to Plasmodium falciparum, remains an enormous problem, especially in Africa. For the last two decades, artemisinin-based combination therapy (ACT) has been recommended for the trea...

www.thelancet.com

2 1

The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 7d

New Personal View:

Reconsidering the clinical assessment of resistance to slowly eliminated antimalarial drugs in high-transmission settings

www.thelancet.com/journals/lan...

Reconsidering the clinical assessment of resistance to slowly eliminated antimalarial drugs in high-transmission settings

Therapeutic efficacy surveillance (TES) is the current WHO recommended method of assessing antimalarial treatment efficacy in vivo. TES has considerable limitations: it is logistically demanding, expe...

www.thelancet.com

1 4 4

The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 7d

New comment:

Long COVID is here to stay—even in children

www.thelancet.com/journals/lan...

Long COVID is here to stay—even in children

Post-acute sequelae of SARS-CoV-2 infection (PASC, also known as long COVID) are complex, multisystem, long-lasting complications of SARS-CoV-2 infection that profoundly impact the daily life of those...

www.thelancet.com

1 5 9

The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 7d

New Research:

Long COVID associated with SARS-CoV-2 reinfection among children and adolescents in the omicron era (RECOVER-EHR): a retrospective cohort study

www.thelancet.com/journals/lan...

Long COVID associated with SARS-CoV-2 reinfection among children and adolescents in the omicron era (RECOVER-EHR): a retrospective cohort study

Children and adolescents face a significantly higher risk of various PASC outcomes after reinfection with SARS-CoV-2. These findings add to previous evidence linking paediatric long COVID to multisyst...

www.thelancet.com

2 3 5

Reposted by The Lancet Infectious Diseases

The Lancet Global Health @lancetgh.bsky.social · 13d

Our October issue is now live! lnkd.in/eezpGTwq
Featuring:
👉 An Editorial on the burden of NCDs among people of South Asian heritage www.thelancet.com/journals/lan...
👉 A Comment urging global health policy makers to recognise obesity as a disease www.thelancet.com/journals/lan...
#HLM4

The October 2025 cover of The Lancet Global Health, featuring a photograph of a Sikh man shopping in a grocery store

2 3

The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 13d

Read our October issue!

Featuring a trial testing moxidectin for lymphatic filariasis, bedaquiline resistance and tuberculosis outcomes, and a recombinant influenza vaccine for children.

www.thelancet.com/issue/S1473-...

1 7 8

The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 14d

New comment:

A new monoclonal in the arMAMentarium against malaria

www.thelancet.com/journals/lan...

A new monoclonal in the arMAMentarium against malaria

The WHO Global Malaria Programme recently started promoting a rather bold idea: monoclonal antibodies—currently among the priciest pharmaceutical products—to prevent a poverty-related disease in low-i...

www.thelancet.com

The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 14d

New Research:

Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial

www.thelancet.com/journals/lan...

Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial

MAM01 was well tolerated, met safety targets, and showed clinical proof-of-principle by eliciting protection in malaria-naive adults using the controlled human malaria infection model. Progress drivin...

www.thelancet.com

1 1 1

The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 14d

🗓️ Saleha Hassan will be attending the Global AMR Innovators Conference, #GAMRIC2025 (1-3 October) in London on behalf of The Lancet Infectious Diseases!

📧Feel free to reach out with enquiries. Explore our scope, reach & impact, commitment to publishing excellence, & more: hubs.li/Q03BL6Th0

1 1

The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 14d

New Comment:

A new monoclonal in the arMAMentarium against malaria

www.thelancet.com/journals/lan...

A new monoclonal in the arMAMentarium against malaria

The WHO Global Malaria Programme recently started promoting a rather bold idea: monoclonal antibodies—currently among the priciest pharmaceutical products—to prevent a poverty-related disease in low-i...

www.thelancet.com

The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 14d

New comment:

A new monoclonal in the arMAMentarium against malaria

www.thelancet.com/journals/lan...

A new monoclonal in the arMAMentarium against malaria

The WHO Global Malaria Programme recently started promoting a rather bold idea: monoclonal antibodies—currently among the priciest pharmaceutical products—to prevent a poverty-related disease in low-i...

www.thelancet.com

Reposted by The Lancet Infectious Diseases

The Lancet Microbe @lancetmicrobe.bsky.social · 20d

New comment

#Diagnostics at the frontline: using the Public Accounts Committee report to catalyse the UK’s antimicrobial resistance diagnostics strategy

www.thelancet.com/journals/lan...

#IDSky #ClinMicro #AMR #OpenAccess #OA

3 1

The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 20d

New Personal View:

Breaking the under-reporting cycle for zoonotic diseases in low-income and middle-income countries through national-level integration of community-based surveillance and response: insights from Cameroon, Chad, Côte d’Ivoire, and Mali

www.thelancet.com/journals/lan...

Breaking the under-reporting cycle for zoonotic diseases in low-income and middle-income countries through national-level integration of community-based surveillance and response: insights from Camero...

Zoonotic diseases remain a major threat to both human and animal populations, especially in low-income and middle-income countries. A key challenge in managing these diseases is insufficient coordinat...

www.thelancet.com

3 2

The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 20d

New Research:

Efficacy and safety of ascending doses of orodispersible ivermectin co-administered with albendazole for Trichuris trichiura infections in preschool-aged children in Tanzania: a single-blind, randomised, controlled, dose-ranging, phase 2 trial

www.thelancet.com/journals/lan...

Efficacy and safety of ascending doses of orodispersible ivermectin co-administered with albendazole for Trichuris trichiura infections in preschool-aged children in Tanzania: a single-blind, randomis...

In preschool-aged children with trichuriasis, orodispersible ivermectin showed an increasing cure rate with ascending doses, together with a dose-independent safety profile. Our study paves the way fo...

www.thelancet.com

3 1

Reposted by The Lancet Infectious Diseases

The Lancet @thelancet.com · 21d

The role of AI in infectious diseases is emerging—offering new opportunities for infection prevention, outbreak detection & control.

But challenges like data fragmentation & trust remain.

Explore a new @thelancetinfdis.bsky.social Series ⤵️
bit.ly/4nbkHrh

Infographic panel for the Lancet Infectious Diseases Series, Artificial intelligence and infectious diseases.

6 9

The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 21d

New linked comment:

A safe start for PfSPZ Vaccine, but efficacy in children remains elusive

www.thelancet.com/journals/lan...

A safe start for PfSPZ Vaccine, but efficacy in children remains elusive

Malaria is a major global health challenge, especially in sub-Saharan Africa. In 2023 alone, malaria caused about 597 000 deaths worldwide, mostly in children.1 A safe and effective vaccine for childr...

www.thelancet.com

1

The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 21d

New Research:

Safety, tolerability, and protective efficacy of a radiation-attenuated, whole sporozoite malaria vaccine in children in Gabon: a randomised, double-blind, placebo-controlled, phase 2 trial

www.thelancet.com/journals/lan...

Safety, tolerability, and protective efficacy of a radiation-attenuated, whole sporozoite malaria vaccine in children in Gabon: a randomised, double-blind, placebo-controlled, phase 2 trial

PfSPZ Vaccine is well tolerated and safe, but it did not prevent P falciparum infection in children in Gabon. Whether presumptive treatment during immunisation or more potent PfSPZ vaccines can establ...

www.thelancet.com

1 3 1

Reposted by The Lancet Infectious Diseases

The Lancet Primary Care @lancetprimarycare.bsky.social · Aug 19

🆕📢“As vertical HIV programmes collapse... primary health care, with its syndemic approach and infrastructure for chronic disease management, is well positioned to absorb HIV services while ensuring sustainability”

Read the Viewpoint ➡️ www.thelancet.com/journals/lan...

Conceptual diagram of primary care services and HIV integration. Shows the potential elements of the integrated essential HIV programme. Full integration would mean transfer of HIV programming, staffing, and budgets to the directorate responsible for delivering primary care services.

4 5